Targeted energy metabolism Nash innovative therapy stage 2B positive clinical results

Recently, cirius therapeutics announced that its main candidate drug, msdc-0602k, has significantly improved the liver enzyme level, blood glucose control and insulin resistance of patients in the phase 2B trial of treatment of nonalcoholic steatohepatitis (NASH) The positive results of this trial will support msdc-0602k to enter the phase 3 clinical phase, and the detailed trial data will be published at this year's liver meeting Globally, more than 100 million people have become NASH patients and are expected to exceed 350 million by 2030 As a kind of metabolic inflammation, it is closely related to obesity, diabetes and dyslipidemia Nash is characterized by the accumulation of fat in the liver, inflammation and fibrosis, further leading to cirrhosis and liver function damage At present, the treatment methods are still relatively scarce, and patients need special drugs to be approved Msdc-0602k is the second generation of oral insulin sensitizer Compared with the first generation, its design concept tries to regulate the function of mitochondrial pyruvate carrier (MPC) and reduce the direct activation effect of peroxisome proliferator activated receptor γ (PPAR γ) to the greatest extent, which has better safety while retaining the efficacy Msdc-0602k can selectively bind to MPC and regulate pyruvate to enter mitochondria MPC is a protein complex in the inner membrane of mitochondria, which mediates the rate of pyruvate entering mitochondria Pyruvate is an intermediate product of carbohydrate metabolism and one of the important energy sources of cells Preclinical studies have shown that the regulation of MPC can improve the effects of insulin resistance, fat metabolism and inflammation ▲ post mortem analysis of liver biopsy in patients receiving msdc-0602k (picture source: reference [1]) 402 NASH patients participated in the phase 2B clinical trial named emminence The results showed that compared with baseline, three different doses of msdc-0602k (62.3 mg, 125 mg, 250 mg) significantly reduced the NAFLD activity score (NAS) of patients, with 33.3%, 39.8% and 42.6% of patients having at least two points lower NAS scores The levels of ALT and AST in the treatment group were also improved compared with those in the placebo group The proportion of patients who achieved ALT normalization in the 125 mg and 250 mg dose groups was 20.8% and 33.3%, respectively, compared with 6.8% in the placebo group In addition, all msdc-0602k dose groups showed significant improvement in HbA1c, one of the markers of blood glucose control "The results of this study show that the treatment of msdc-0602k can significantly improve blood glucose control and avoid liver injury," said Mr Bob baltera, chief executive officer of cirius "These test results prove the potential of our new generation of insulin sensitizers in improving liver function, and we hope to promote msdc-0602k to phase 3 test as soon as possible." reference material: [1] Cirius Therapeutics Announces Results from Phase 2b NASH Study Supporting Advancing to Phase 3 Development of MSDC-0602K; Data Accepted for Late Breaker Presentation at The Liver Meeting, Retrieved November 8, 2019, from https:// A kind of